VIDEO
WATCH: Inside the Cancer Calculus investigation — a live Q&A
Go behind the scenes of the Cancer Calculus investigation, and hear insights about Merck’s cancer drug Keytruda from ICIJ’s chief reporter and a health economist.
The International Consortium of Investigative Journalists hosted a live virtual discussion exploring findings of its Cancer Calculus investigation.
The event featured ICIJ chief reporter Sydney P. Freedberg and Serif Health health economist and senior director of analytics Bill Pajerowski. ICIJ digital producer Carmen Molina Acosta led the discussion.
Drawing on reporting with 47 media partners around the world, the Cancer Calculus investigation examines how pharmaceutical industry practices tied to patents, pricing and billing can drive up costs and limit access to lifesaving cancer treatment. The conversation included behind-the-scenes insights into the reporting, key findings from the investigation and why they matter, discussion of broader pharmaceutical pricing practices and an audience Q&A.
For your invitation to future events, please subscribe to ICIJ’s newsletter or consider making a donation to support our work.
Clarification: ICIJ’s investigation found more than 1,200 Keytruda-related patent applications across 53 countries. These were filed by Merck and other cancer research businesses.